Telaprevir-based triple therapy significantly decreases the serum alpha-fetoprotein level in chronic hepatitis C patients: A prospective study
- Conditions
- Chronic hepatitis C
- Registration Number
- JPRN-UMIN000013784
- Lead Sponsor
- Department of General Internal Medicine, Kyushu University Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 200
Not provided
The exclusion criteria were as follows: (1) presence of HCC at enrollment, or development of HCC until 24 weeks after EOT; (2) shortening of treatment due to adverse effect, virological breakthrough, non-virological response (NVR), or dropout; (3) in dual therapy group, extension of standard 48-week therapy; (4) inadequate treatment dose of 80% or less assigned total cumulative dosage of each drug; (5) positivity for antibody to human immunodeficiency virus or positivity for hepatitis B surface antigen; (6) clinical or biochemical evidence of hepatic decompensation (Child-Pugh B or C, ascites, bleeding varices, or encephalopathy) at enrollment; (7) excessive active alcohol consumption (a daily intake of more than 60g of alcohol) or drug abuse; (8) other forms of liver disease (e.g., autoimmune hepatitis, alcoholic liver disease, hemochromatosis); or (9) treatment with antiviral or immunosuppressive agents prior to enrollment.
Study & Design
- Study Type
- Interventional,observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Decline of the AFP level by treatment
- Secondary Outcome Measures
Name Time Method